
    
      The study consisted of a screening period of up to 30 days and a Treatment Period of up to
      253 days for Cohorts 1-3 and 281 days for Cohort 4. After completion of the Treatment Period,
      all participants had the opportunity to enter the Extension Period, wherein participants
      continue to receive ravulizumab for up to 5 years. The first dose in the Extension Period
      occurred on Day 253 for Cohorts 1-3 and on Day 281 for Cohort 4.

      This study is ongoing. The data presented includes the Primary Completion date of the study
      for the Treatment Period. The results for the Extension Period will be reported after study
      completion.
    
  